STOCK TITAN

Barinthus Biotherapeutics plc - $vacc STOCK NEWS

Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: $vacc), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Barinthus Biotherapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Barinthus Biotherapeutics plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
Barinthus Biotherapeutics plc

Nasdaq:VACC

VACC Rankings

VACC Stock Data

192.73M
28.30M
3.46%
49.84%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Harwell

About VACC

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit